Core Insights - A hair loss treatment product from Mandi International, a subsidiary of Sangfor Pharmaceutical, is set to go public on the Hong Kong Stock Exchange, potentially marking the third IPO for the Liu family [1] - Mandi International holds a significant 57% market share in China's hair loss medication market, driven by its flagship product, Mandi® Minoxidil [1][4] - Despite strong financial performance, Mandi International faces challenges such as product concentration, reduced R&D investment, and increasing competition [1][7] Financial Performance - Mandi International's revenue projections for 2022 to 2024 are 982 million RMB, 1.228 billion RMB, and 1.455 billion RMB, with net profits of 202 million RMB, 441 million RMB, and 309 million RMB respectively [2] - In the first half of 2025, the company reported revenue of 743 million RMB, a 20.2% increase year-on-year, and a net profit of 174 million RMB, up 64.1% [2] - The gross margin for the company has remained high, with figures of 80.3%, 82.0%, 82.7%, and 81.1% from 2022 to 2025 [3] Product Structure - Over 90% of Mandi International's revenue comes from the Mandi® product line, with the core product Mandi® 5% Minoxidil accounting for 91.3% and 91.6% of revenue in 2022 and 2023 respectively [4] - The company is expanding its product line to include other skin care products and is developing a long-acting GLP-1 receptor agonist for weight management, currently in Phase III clinical trials [6] R&D and Marketing - Mandi International's R&D expenses saw a significant drop from 92.2 million RMB in 2024 to 19.5 million RMB in the first half of 2025, raising concerns about its innovation capabilities [7] - In contrast, sales expenses have increased, reaching 374 million RMB in the first half of 2025, which is over 50% of total revenue [9] Market Competition - The hair loss treatment market is becoming increasingly competitive, with major players like Merck and Johnson & Johnson entering the space [12] - Mandi International's core patents are set to expire in 2028, which could lead to a surge in generic products and price competition [12] - The number of registered hair loss shampoos in China has exceeded 400, indicating a crowded market [12] Industry Trends - The global hair loss medication market is projected to reach $2.11 billion in 2024 and $3.175 billion by 2031, with a CAGR of 6.1% [12] - The rising interest in consumer healthcare and the potential for high-margin, self-purchased products are attracting capital market attention [13]

Core Viewpoint - A hair loss treatment product from Mandi International, a subsidiary of 3SBio, is expected to lead to a third IPO for the Liu family, amidst a growing hair loss crisis in China, where over 330 million people are affected, with more than 60% under the age of 35 [2][4]. Financial Performance - Mandi International reported impressive financial data, with revenues projected to reach RMB 9.82 billion, RMB 12.28 billion, and RMB 14.55 billion from 2022 to 2024, and net profits of RMB 2.02 billion, RMB 4.41 billion, and RMB 3.09 billion respectively [6]. - In the first half of 2025, the company achieved revenue of RMB 7.43 billion, a year-on-year increase of 20.2%, and a net profit of RMB 1.74 billion, up 64.1% [6]. Product Concentration - Over 90% of Mandi International's revenue comes from the Mandi® product series, with the core product, Mandi® 5% Minoxidil solution, accounting for 91.3% and 91.6% of revenue in 2022 and 2023 respectively [7][8]. R&D and Marketing Expenditure - Despite strong performance, Mandi International's R&D spending saw a significant drop from RMB 9.22 million in 2024 to RMB 1.95 million in the first half of 2025, raising concerns about its innovation capabilities [11]. - Sales expenses have increased significantly, with over 50% of revenue in the first half of 2025 allocated to sales costs, indicating rising customer acquisition costs in a competitive market [13][14]. Market Competition - The hair loss treatment market is becoming increasingly competitive, with major players like Merck and Johnson & Johnson entering the space. The global market for hair loss treatment is projected to reach USD 2.11 billion in 2024, growing at a CAGR of 6.1% [18]. - Mandi International faces potential risks as some of its core patents are set to expire in 2028, which could lead to a flood of generic products and price wars [18]. Industry Trends - The rising incidence of hair loss among younger demographics is transforming "hair health" into a significant consumer pharmaceutical category, attracting capital market interest [19]. - The company's ability to innovate and diversify its product pipeline will be crucial for its future growth potential, especially in a market that has shown clear demand [19].

Core Viewpoint - The article discusses the growing market for hair loss treatments in China, highlighting the upcoming IPO of Mandi International and the significant market potential driven by a large population suffering from hair loss, particularly among younger individuals [2][11]. Company Overview - Mandi International, originally founded in 2001, has established itself in the hair loss treatment sector with its Minoxidil products, including a 5% Minoxidil solution and foam [3][6]. - The company was acquired by 3SBio in 2015, which has since expanded its market presence and product offerings [3][4]. Market Potential - Over 330 million people in China suffer from hair loss, with more than 60% of this demographic being under 35 years old, indicating a substantial market opportunity [2][11]. - Mandi's Minoxidil products hold a market share of 57% in the domestic hair loss medication sector and 71% in the Minoxidil category, maintaining a leading position for ten consecutive years [6]. Financial Performance - Mandi International's revenue has shown a compound annual growth rate (CAGR) of 21.7% from 2022 to 2024, with revenues of 982 million RMB, 1.228 billion RMB, and 1.455 billion RMB for those years respectively [8]. - The gross profit margins have remained high, with figures of 80.3%, 82.0%, and 82.7% for the same period [8]. Product Portfolio - The product lineup includes first-generation and second-generation Minoxidil products, as well as a range of shampoos with various benefits [6][8]. - The company is also developing additional products for acne treatment and weight management, with plans for regulatory submissions in the coming years [8]. Distribution Channels - Mandi International's online sales have increased significantly, with online sales accounting for 74% of total sales by mid-2025, up from 55.2% in 2022 [9]. - However, the number of offline distributors has decreased by 51.8% over three years, indicating potential risks in customer retention [10]. Competitive Landscape - The hair loss treatment market is becoming increasingly competitive, with rising customer acquisition costs and price reductions impacting profit margins [10]. - The article notes the emergence of various brands entering the market, including those from established companies like Proya and Vichy, which are launching their own anti-hair loss products [12].

Core Viewpoint - Sanofi Pharmaceutical (01530) experienced a decline of over 8%, specifically 8.33%, trading at HKD 29.7 with a transaction volume of HKD 495 million following the announcement of a proposed spin-off of its subsidiary, Mandi [1] Group 1: Company Announcement - On November 20, Sanofi Pharmaceutical announced its proposal to spin off its subsidiary, Mandi, for independent listing on the Hong Kong Stock Exchange [1] - The proposed spin-off is expected to be executed through a physical distribution of Mandi shares to shareholders based on their respective holdings in the company, along with a global offering of new Mandi shares [1] - Mandi International submitted its listing application to the Hong Kong Stock Exchange yesterday [1] Group 2: Ownership Structure - As of the announcement date, Mandi is beneficially owned by Sanofi Pharmaceutical (approximately 87.16%), Yingtai Management Limited (3.38%), Mandi Group Limited (2.80%), GL Wecan Investment IV L.P. (4.00%), and Alibaba Health (Hong Kong) Technology Co., Ltd. (2.65%) [1] Group 3: Mandi's Market Position - Mandi focuses on the hair health sector within the broader skin health industry and has established a leading position [1] - Mandi launched the first domestic 5% minoxidil solution under the Mandi® brand in 2001 and plans to introduce a second-generation minoxidil product, Mandi® 5% minoxidil foam, in 2024 [1]

Core Viewpoint - The company plans to spin off its subsidiary Mandi Group and list it independently on the Hong Kong Stock Exchange, which is expected to enhance shareholder value and provide greater market visibility for Mandi [1][2]. Group 1: Spin-off Details - The proposed spin-off will involve a distribution of Mandi shares to existing shareholders based on their ownership percentage in the company, along with a global offering of new Mandi shares [1]. - Mandi submitted its application to the Stock Exchange on November 20, 2025, for the approval of its shares to be listed and traded on the main board [1]. Group 2: Ownership Structure - As of the announcement date, Mandi is beneficially owned by the company (approximately 87.16%), along with other entities including Intai Management Limited, Mandi Group Limited, GL Wecan Investment IV L.P., and Alibaba Health (Hong Kong) Technology Co., Ltd. [2]. Group 3: Company Profile - Mandi is recognized as a leading professional consumer pharmaceutical company in China, focusing on comprehensive and long-term solutions for skin health and weight management [2]. - The company has established a leadership position in the hair health sector within the broader skin health industry, having launched the first 5% minoxidil solution under the Mandi® brand in 2001 [2]. - In 2024, Mandi plans to introduce a second-generation minoxidil product, the Mandi® 5% minoxidil foam [2].